Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 5/20 | 0.52 |
| ▸ | FLT3 | P36888 | 2/20 | 0.44 |
| ▸ | ADK | P55263 | 4/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | BCR | P11274 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL868512 | 0.84 | ADK (0.39) | METTL3FLT3ADKTLR7SMN1; SMN2 | |
| SCHEMBL10261380 | 0.84 | FLT3 (0.47) | METTL3FLT3ADKMETAXL | |
| SCHEMBL6927366 | 0.81 | FLT3 (0.45) | METTL3FLT3METAXLTLR7 | |
| SCHEMBL20351665 | 0.79 | FLT3 (0.58) | FLT3METAXLABL1MEN1 | |
| SCHEMBL29780909 | 0.77 | ADK (0.45) | METTL3FLT3ADKABL1 | |
| SCHEMBL29052158 | 0.77 | ADK (0.45) | METTL3FLT3ADKABL1 | |
| SCHEMBL3957869 | 0.74 | ADORA2A (0.60) | TLR7SMN1; SMN2 | |
| SCHEMBL869273 | 0.74 | SRC (0.46) | FLT3ADKABL1 | |
| SCHEMBL868932 | 0.74 | FLT3 (0.42) | FLT3ADKABL1 | |
| SCHEMBL28972374 | 0.74 | FLT3 (0.72) | FLT3METAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2549868-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-01-07 | — | — | EP | disclosed |
| US-8598156-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-12-03 | — | — | US | disclosed |
| CN-102917588-A | Chemical compounds | GLAXOSMITHKLINE LLC | 2013-02-06 | — | — | CN | disclosed |
| EP-2549868-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | METTL3 4319/4885FLT3 2923/4885ADK 1509/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | METTL3 4319/4885FLT3 2923/4885ADK 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.